Development and validation of a reversed-phase fluorescence HPLC method for determination of bucillamine in human plasma using pre-column derivatization with monobromobimane.
A simple, specific and sensitive derivatization with monobromobimane (mBrB) and the corresponding HPLC-fluorescence quantitation method for the analysis of bucillamine in human plasma was developed and validated. The analytical procedure involves a simple protein precipitation, pre-column fluorescence derivatization, and separation by reversed-phase high performance liquid chromatography (RP-HPLC). The calibration curve showed good linearity over a wide concentration range (50 ng/mL to 10 microg/mL) in human plasma (r(2)=0.9998). The lower limit of quantitation (LLOQ) was 50 ng/mL. The average precision and accuracy at LLOQ were within 6.3% and 107.6%, respectively. This method was successfully applied to a pharmacokinetic study after oral administration of a dose (300 mg) of bucillamine to 20 healthy Korean volunteers.
Lee
Kang Choon
KC
College of Pharmacy, SungKyunKwan University, 300 Chonchon-dong, Jangan-ku, Suwon 440-746, Republic of Korea.
Chun
Young Goo
YG
Kim
Insoo
I
Shin
Beom Soo
BS
Park
Eun-Seok
ES
Yoo
Sun Dong
SD
Youn
Yu Seok
YS
D018501:Antirheumatic Agents / Q000097:blood* / Q000493:pharmacokinetics; D001643:Bridged Bicyclo Compounds / Q000737:chemistry*; D002851:Chromatography, High Pressure Liquid / Q000295:instrumentation / Q000379:methods*; D003545:Cysteine / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D005456:Fluorescent Dyes / Q000737:chemistry*; D006801:Humans; D008297:Male
D018501:Antirheumatic Agents; D001643:Bridged Bicyclo Compounds; D005456:Fluorescent Dyes; D003545:Cysteine; C026535:bucillamine; C028381:monobromobimane